---
title: "blinatumomab"
slug: "blinatumomab"
date: "2024-01-23"
enableToc: false
tags:
  - building
---

> [!info]
>
> 🌱 來自：[[relapse refractory of treatment of acute lymphoblastic leukemia (ALL)]]

# blinatumomab

> bispecific T-cell-engaging (BiTE) antibody against CD19
> bli-na-TUMO-mab

- Mechanism:
  - Binds CD19 on malignant B-cells & CD3 on T-cells
- Dosing:
  - Cycle 1:9-mcg continuous infusion daily (d 1-7),
  - followed by 28-mcg continuous infusion daily (d 8-28); cycle 2-5: 28-mcg continuous infusion daily (1-28) every 6 wks;. Cycles for MRD: 28-mcg continuous infusion
- PK/PD: T1/2 ∼2 h
- AEs: CRS, neurologic tox, fever, peripheral edema, diarrhea, ↑ liver enzymes
- DDI: No known pathways of metabolism, avoid live, & inactivated vaccines
- Clinical pearls:
  - Admission required for initiation & for subsequent cycles for varying duration dependent on disease burden

- CD19 BiTE-bispecific T-cell engager; NEJM2017;376:836
- B 型白血病：百利妥(Blinatumomab, Blincyto)
- 健保給付使用在頑固型或是復發型的 B 細胞型急性淋巴性白血病。

---

- 雙特異性 T 細胞接合器，
- 引導體內 CD3 T cell，
- 🚫具有 CD19 標記的 B 細胞 (急性淋巴性白血病的癌細胞) 為目標

---

- 進行連結，活化內生的 T 細胞
- 活化的 T 細胞會影響癌細胞的突觸生成
- 進而增加 ↑ 細胞黏附分子
- 產生 ↪ 細胞溶蝕蛋白與釋出發炎性細胞激素
- 最終使具有 CD19 標記的癌細胞導向死亡

### Backlink

- [[relapse refractory of treatment of acute lymphoblastic leukemia (ALL)]]
- [[acute lymphoblastic leukemia]]
- [[Monoclonal Antibodies]]
